Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.
- Gudmundsson, J.
- Sulem, P.
- Manolescu, A.
- Amundadottir, L.T.
- Gudbjartsson, D.F.
- Helgason, A.
- Rafnar, T.
- Bergthorsson, J.T.
- Agnarsson, B.A.
- Baker, A.
- Sigurdsson, A.
- Benediktsdottir, K.R.
- Jakobsdottir, M.
- Xu, J.
- Blondal, T.
- Kostic, J.
- Sun, J.
- Ghosh, S.
- Stacey, S.N.
- Mouy, M.
- Saemundsdottir, J.
- Backman, V.M.
- Kristjansson, K.
- Tres, A.
- Partin, A.W.
- Albers-Akkers, M.T.
- Marcos, J.G.I.
- Walsh, P.C.
- Swinkels, D.W.
- Navarrete, S.
- Isaacs, S.D.
- Aben, K.K.H.
- Graif, T.
- Cashy, J.
- Ruiz-Echarri, M.
- Wiley, K.E.
- Suarez, B.K.
- Witjes, J.A.
- Frigge, M.
- Ober, C.
- Jonsson, E.
- Einarsson, G.V.
- Mayordomo, J.I.
- Kiemeney, L.A.L.M.
- Isaacs, W.B.
- Catalona, W.J.
- Barkardottir, R.B.
- Gulcher, J.R.
- Thorsteinsdottir, U.
- Kong, A.
- Stefansson, K.
DOIAbstract
Prostate cancer is the most prevalent noncutaneous cancer in males in developed regions, with African American men having among the highest worldwide incidence and mortality rates. Here we report a second genetic variant in the 8q24 region that, in conjunction with another variant we recently discovered, accounts for about 11%-13% of prostate cancer cases in individuals of European descent and 31% of cases in African Americans. We made the current discovery through a genome-wide association scan of 1,453 affected Icelandic individuals and 3,064 controls using the Illumina HumanHap300 BeadChip followed by four replication studies. A key step in the discovery was the construction of a 14-SNP haplotype that efficiently tags a relatively uncomm...
Add to ORKG